查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423568

到 2030 年非注射胰島素市場預測：按產品、劑量、分銷管道和地區進行的全球分析

Non-Injectable Insulin Market Forecasts to 2030 - Global Analysis By Product (Oral, Transdermal, Nasal, Sublingual and Other Products), Dosage, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球非注射胰島素市場規模將達到 14 億美元，預計到 2030 年將達到 40 億美元，預測期內複合年成長率為 15.2%。

非注射型胰島素是指不需要將針頭插入皮膚，而是可以用其他方法給藥的胰島素型態。這些技術可以作為貼劑局部應用，也可以透過吸入、口服藥物或鼻噴劑來應用。隨著非注射胰島素的引入，需要胰島素治療的人將有一個更方便的選擇，這可能會提高治療醫囑遵從性並全面改善生活品質。

據 Biocon 稱，口服胰島素製劑 Tregopil 用於 1 型糖尿病的 1 期試驗已於 2022 年 6 月結束，但用於第 2 型糖尿病的 3 期試驗仍在繼續。

藥物傳輸技術開發

藥物輸送技術的不斷進步是市場成長的主要驅動力。由於這些創新技術的進步，糖尿病管理領域正在發生變化，使非注射胰島素替代品更加可靠、高效，並且對患者和醫療保健專業人員都有吸引力。此外，這些發展正在提高胰島素劑量的準確性和一致性，並提高非注射胰島素裝置的整體有效性。

副作用

與任何藥物一樣，非注射胰島素也有副作用。吸入胰島素可能會引起咳嗽和喉嚨發炎。口服胰島素可能與消化酵素相互作用或引起胃腸道問題。患者不願意使用非注射胰島素產品是該市場成長的主要障礙。即使非注射胰島素替代品有明顯的優勢和易用性，有些人仍不願放棄舒適且公認的胰島素注射方法。

糖尿病盛行率上升

隨著糖尿病在世界各地變得越來越普遍，替代胰島素輸送系統也越來越普及。對於不願意注射或注射有困難的糖尿病患者來說，非注射替代品可能是個令人信服的替代品。向患者、醫療保健專業人員和公眾宣傳非注射胰島素解決方案的可用性和優點的舉措也推動了採用率的提高和市場擴張。

高成本

如果核准，非注射胰島素的成本可能會比傳統的注射胰島素更高。由於輸送系統的研發和技術進步，成本可能會增加。然而，監管機構在開發和核准非注射胰島素方面遇到了困難。通常需要進行監管審查和長期臨床試驗，以確保一般用途的安全性和有效性。這些因素阻礙了市場擴張。

COVID-19 的影響：

非注射胰島素市場受到 COVID-19 大流行的各種影響。儘管最初出現供應鏈中斷和醫療保健設施有限的情況，但對糖尿病治療創新解決方案的需求仍在增加。隨著患者尋找替代品以減少就診次數，對非注射胰島素產品的需求增加。此外，這種流行病加速了遠端醫療的使用，使患者更容易獲得並與醫療保健專業人員討論這些選擇。

噴霧產業預計在預測期內規模最大

由於噴霧劑的便利性和對患者友好的特性，預計在預測期內將成長最大。尋求一種更簡單、更少令人不快的方法來控制糖尿病的患者可能會發現吸入式胰島素噴霧劑作為注射的侵入性較小的替代品很有吸引力。此外，隨著藥物傳遞技術的重大發展，這些噴霧可確保準確且有效的劑量。

醫院藥房業務預計在預測期內複合年成長率最高

醫院藥房業務預計在預測期內複合年成長率最高。醫療機構在糖尿病的管理和治療中發揮著至關重要的作用，也是提供非注射胰島素產品的重要中心。醫院的臨床背景增強了人們對非注射胰島素製劑的信心。這種變數的組合使得醫院藥房普及和提供非注射胰島素製劑，從而使廣泛的患者群體受益。

比最大的地區

預計北美在預測期內將佔據最大的市場佔有率。該地區的糖尿病患病率高、醫療基礎設施強大以及對研究和創新的重視造就了其優勢。特別值得注意的是患者對改用非注射胰島素產品的意識和準備程度。該地區對方便且以患者為中心的糖尿病治療解決方案的強烈需求鞏固了該地區巨大的市場佔有率。

複合年成長率最高的地區：

預計亞太地區在預測期內複合年成長率最高。該地區糖尿病患病率高、都市化速度快、醫療基礎設施不斷擴大，導致對創新糖尿病管理解決方案的需求增加。政府舉措以及與製藥公司的合作夥伴關係正在進一步支持市場擴張。由於我們龐大且多樣化的患者群體以及令人鼓舞的醫療保健計劃，這使我們成為該市場的重要參與者。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球非注射胰島素市場：按產品

  • 口服
  • 經皮的
  • 鼻腔
  • 舌下
  • 其他產品

第6章全球非注射胰島素市場：按劑量

  • 藥丸
  • 噴

第7章全球非注射胰島素市場：按分銷管道

  • 醫院藥房
  • 網路商店
  • 藥局

第8章全球非注射胰島素市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Generex Biotechnology Corp.
  • Biodel, Inc.
  • Oramed Pharmaceuticals, Inc.
  • Diasome Pharmaceuticals, Inc.
  • Midatech Pharma Plc
  • Shreya Life Sciences Pvt. Ltd.
  • Boston Therapeutics, Inc.
  • Diabetology Ltd.
  • Emisphere Technologies, Inc.
  • Coromed, Inc.
  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • MannKind Corporation
  • Adocia
  • Oramed Pharmaceuticals
  • Dance Biopharm
  • Biocon
  • Janssen Pharmaceuticals
Product Code: SMRC24802

According to Stratistics MRC, the Global Non-Injectable Insulin Market is accounted for $1.4 billion in 2023 and is expected to reach $4.0 billion by 2030 growing at a CAGR of 15.2% during the forecast period. Non-injectable insulin refers to forms of insulin that do not require injection through a needle into the skin but instead can be administered through alternative methods. These techniques can be applied topically as patches or through inhalation, oral medication, or nasal sprays. With the introduction of non-injectable insulin, people who need insulin therapy will have more convenient options, which could lead to better treatment adherence and an overall improvement in quality of life.

According to Biocon, it terminated its phase 1 trial of oral Insulin Tregopil for Type 1 diabetes mellitus in June 2022, while continuing phase 3 trials for Type 2 diabetes mellitus

Market Dynamics:

Driver:

Technological developments in medicine delivery

The continuous progress in medication delivery technology is a major driver of the market's growth. The field of diabetes management is changing as a result of these innovative technical advancements, which make non-injectable insulin substitutes more dependable, efficient, and appealing to patients and medical professionals alike. Furthermore, these developments have improved insulin dose accuracy and consistency, increasing the overall effectiveness of non-injectable insulin devices.

Restraint:

Side effects

Like any medication, non-injectable insulin can have side effects. Inhaled insulin might cause coughing or throat irritation. Oral insulin might interact with digestive enzymes or cause gastrointestinal issues. The reluctance of patients to embrace non-injectable insulin techniques presents a significant obstacle to the market's growth. Even with the obvious benefits and ease of use of non-injectable insulin alternatives, some people are reluctant to abandon the comfortable and well-recognized method of insulin injections.

Opportunity:

Rising diabetes prevalence

Alternative insulin administration systems are becoming more and more popular as diabetes becomes more commonplace worldwide. Non-injectable alternatives present a compelling substitute for diabetes individuals who may be uncomfortable with or struggle with injections. Increased adoption and market expansion are also facilitated by initiatives to inform patients, medical professionals, and the general public about the availability and advantages of non-injectable insulin solutions.

Threat:

High cost

If approved, non-injectable insulin may cost more than conventional injectable insulin. Expenses may rise as a result of R&D and technological advancements in delivery systems. Regulators have encountered difficulties with the development and approval of non-injectable insulin, though. Regulatory scrutiny and lengthy clinical trials are frequently necessary to ensure safety and efficacy for general use. The market's expansion is being hindered by these factors.

Covid-19 Impact:

The market for non-injectable insulin has been affected by the COVID-19 pandemic in a variety of ways. The initial interruption of the supply chain and limited accessibility to healthcare facilities notwithstanding, there was an increasing demand for creative solutions to treat diabetes. There was an increase in demand for non-injectable insulin options as patients looked for alternatives to lessen their hospital visits. In addition, the epidemic hastened the use of telemedicine, facilitating patient access to and discussion of these choices with medical professionals.

The sprays segment is expected to be the largest during the forecast period

The sprays segment is expected to be the largest during the forecast period due to its convenience and patient-friendly attributes. Patients looking for simpler and less unpleasant ways to manage their diabetes may find inhalable insulin sprays appealing as a less intrusive substitute for injections. Furthermore, these sprays guarantee accurate and efficient dosage due to notable developments in drug delivery technology.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period. Healthcare facilities play a pivotal role in the management and treatment of diabetes, rendering them notable hubs for the delivery of insulin products that are not injectable. Trust in non-injectable insulin alternatives is fostered by the clinical context of hospitals. A broad patient population can benefit from the promotion and provision of non-injectable insulin solutions by hospital pharmacy due to the confluence of these variables.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. High diabetes prevalence, a robust healthcare infrastructure, and a strong emphasis on research and innovation in the region contribute to its prominence. Notable are the patient's awareness and readiness to switch to non-injectable insulin substitutes. The region's significant market share is cemented by the high need for accessible and patient-focused diabetes treatment solutions.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The region's high diabetes prevalence, rapid urbanization, and expanding healthcare infrastructure have contributed to increased demand for innovative diabetes management solutions. Initiatives from the government and partnerships with pharmaceutical firms have further encouraged market expansion. Because of this, it is positioned as a significant player in the market thanks to its large and diverse patient population and encouraging healthcare programs.

Key players in the market

Some of the key players in Non-Injectable Insulin market include Generex Biotechnology Corp., Biodel, Inc., Oramed Pharmaceuticals, Inc., Diasome Pharmaceuticals, Inc., Midatech Pharma Plc, Shreya Life Sciences Pvt. Ltd., Boston Therapeutics, Inc., Diabetology Ltd., Emisphere Technologies, Inc., Coromed, Inc., Novo Nordisk, Sanofi, Eli Lilly, MannKind Corporation, Adocia, Oramed Pharmaceuticals, Dance Biopharm, Biocon and Janssen Pharmaceuticals.

Key Developments:

In November 2023, Eli Lilly and Company announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company's global parenteral (injectable) product and device manufacturing network and support an increased demand for Lilly's medicines, including its diabetes and obesity portfolio.

In February 2022, Biocon made a significant move by acquiring Viatris' biosimilar portfolio for a substantial sum of USD 3.335 billion. This strategic acquisition bolstered Biocon's biosimilar product offerings and had a positive impact on the company's revenue generation.

Products Covered:

  • Oral
  • Transdermal
  • Nasal
  • Sublingual
  • Other Products

Dosages Covered:

  • Pills
  • Sprays

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Stores
  • Drug Stores

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Non-Injectable Insulin Market, By Product

  • 5.1 Introduction
  • 5.2 Oral
  • 5.3 Transdermal
  • 5.4 Nasal
  • 5.5 Sublingual
  • 5.6 Other Products

6 Global Non-Injectable Insulin Market, By Dosage

  • 6.1 Introduction
  • 6.2 Pills
  • 6.3 Sprays

7 Global Non-Injectable Insulin Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Online Stores
  • 7.4 Drug Stores

8 Global Non-Injectable Insulin Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Generex Biotechnology Corp.
  • 10.2 Biodel, Inc.
  • 10.3 Oramed Pharmaceuticals, Inc.
  • 10.4 Diasome Pharmaceuticals, Inc.
  • 10.5 Midatech Pharma Plc
  • 10.6 Shreya Life Sciences Pvt. Ltd.
  • 10.7 Boston Therapeutics, Inc.
  • 10.8 Diabetology Ltd.
  • 10.9 Emisphere Technologies, Inc.
  • 10.10 Coromed, Inc.
  • 10.11 Novo Nordisk
  • 10.12 Sanofi
  • 10.13 Eli Lilly
  • 10.14 MannKind Corporation
  • 10.15 Adocia
  • 10.16 Oramed Pharmaceuticals
  • 10.17 Dance Biopharm
  • 10.18 Biocon
  • 10.19 Janssen Pharmaceuticals

List of Tables

  • Table 1 Global Non-Injectable Insulin Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 4 Global Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 5 Global Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 6 Global Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 7 Global Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 9 Global Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 10 Global Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 11 Global Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 12 Global Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 13 Global Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 14 Global Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 15 North America Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
  • Table 16 North America Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 17 North America Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 18 North America Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 19 North America Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 20 North America Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 21 North America Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 22 North America Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 23 North America Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 24 North America Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 25 North America Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 26 North America Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 27 North America Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 28 North America Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 29 Europe Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
  • Table 30 Europe Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 31 Europe Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 32 Europe Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 33 Europe Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 34 Europe Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 35 Europe Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 36 Europe Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 37 Europe Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 38 Europe Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 39 Europe Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 40 Europe Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 41 Europe Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 42 Europe Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 43 Asia Pacific Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Asia Pacific Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 45 Asia Pacific Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 46 Asia Pacific Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 47 Asia Pacific Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 48 Asia Pacific Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 49 Asia Pacific Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 50 Asia Pacific Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 51 Asia Pacific Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 52 Asia Pacific Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 53 Asia Pacific Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 54 Asia Pacific Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 55 Asia Pacific Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 56 Asia Pacific Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 57 South America Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
  • Table 58 South America Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 59 South America Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 60 South America Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 61 South America Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 62 South America Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 63 South America Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 64 South America Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 65 South America Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 66 South America Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 67 South America Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 68 South America Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 69 South America Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 70 South America Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 71 Middle East & Africa Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
  • Table 72 Middle East & Africa Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 73 Middle East & Africa Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 74 Middle East & Africa Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 75 Middle East & Africa Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 76 Middle East & Africa Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 77 Middle East & Africa Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 78 Middle East & Africa Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 79 Middle East & Africa Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 80 Middle East & Africa Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 81 Middle East & Africa Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 82 Middle East & Africa Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 83 Middle East & Africa Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 84 Middle East & Africa Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)